key: cord-0743672-bz71tdh4 authors: Balkhair, A; Al-Zakwani, I.; Al Busaidi, M.; Al-Khirbash, A.; Al Mubaihsi, S.; BaTaher, H.; Al Aghbari, J.; Al Busaidi, I.; Al Kindi, M.; Baawain, S.; Al Alawi, A.; Al Lawati, A.; Al Rawahi, B.; Al-Baimani, K.; Al Zidi, K.; Elfatih, N.; Dawud, B.; John, B.; Rehman, F.; Yousif, F.; Al Khadouri, G.; Saber, I.; Lal, J.; Gargouri, M.; Al-Ward, M.; AbuDraz, N.; Al Ruqeishi, S.; Kumar, S.; Abdelmottaleb, W.; Al-Naamani, Z.; Bin Nazar, Z.; Balkhair, O. title: Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study date: 2020-11-17 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2020.11.149 sha: ac6c3ac551ef51e1e5fd92fe19dd04afe5984e09 doc_id: 743672 cord_uid: bz71tdh4 OBJECTIVE: To evaluate the efficacy of anakinra in patients who were admitted to hospital for severe COVID-19 pneumonia requiring high oxygen therapy. METHODS: A prospective, open-label, interventional study in adults hospitalized with severe COVID-19 pneumonia was conducted. Patients in the interventional arm received subcutaneous anakinra (100 mg twice daily for 3 days, followed by 100 mg daily for 7 days) in addition to standard treatment. Main outcomes were need for mechanical ventilation and in-hospital death. Secondary outcomes included successful weaning from supplemental oxygen and change in inflammatory biomarkers. Outcomes were compared with those of historical controls who received standard treatment and supportive care. RESULTS: A total of 69 patients were included; 45 anakinra-treated and 24 historical controls. Need for mechanical ventilation occurred in 14 (31%) in the anakinra-treated group and 18 (75%) in the historical cohort (p < 0.001). In-hospital death occurred in 13 (29%) in the anakinra-treated group and 11 (46%) in the historical cohort (p = 0.082). Successful weaning from supplemental oxygen to ambient air was attained in 25 (63%) in the anakinra-treated compared with 6 (27%) in the historical cohort (p = 0.008). Patients who received anakinra showed significant reduction in inflammatory biomarkers. CONCLUSION: In patients with severe COVID-19 pneumonia and high oxygen requirement, anakinra could represent an effective treatment option and may confer clinical benefit. TRIAL REGISTRATION NUMBER: ISRCTN74727214. The coronavirus disease 19 pandemic, instigated by the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused more than 36 million cases and over 1 million deaths worldwide as of 9 October 2020 (World Health Organization, 2020). While the majority of symptomatic COVID-19 cases are mild, approximately 5% develop severe illness with abrupt clinical deterioration and rapid progression to acute hypoxic respiratory failure often requiring advanced respiratory support (Wu and McGoogan, 2020) . This worsening typically coincides with declining viral titres and usually occurs 7-10 days after onset of symptoms (Joynt and Wu 2020) . Patients during this phase frequently exhibit extreme increase in proinflammatory cytokines, especially, interleukin-1 (IL-1), interleukin-6 (IL-6), and interleukin-10 (IL-10) leading to the end state of hyperinflammation (Yang et al., 2020; Petrilli et al., 2020) . IL-1 is an extremely potent proinflammatory cytokine which has been linked to SARS-CoV-2 induced lung injury (Liao et al., 2020) , implicated in the pathogenesis of the inflammatory phase of COVID-19 (Bordoni et al., 2020) , and may serve as therapeutic target for COVID-19 pneumonia (Ong et al., 2020) . It is becoming increasingly recognized that there are two distinct, albeit overlapping pathologic and phenotypic subsets of COVID-19 pneumonia namely viral pneumonitis and viral-triggered overreacting immune response (Siddiqi and Mehra, 2020) . The latter phenotype is the most severe form and is typified by rapid progression to acute respiratory failure often requiring invasive ventilatory support (Yang et al., 2020) . Patients with severe COVID-19 pneumonia on invasive ventilatory support have excessive mortality (Karagiannidis et al., 2020) . This excess death is mostly attributed to boisterous hyperinflammation resulting in severe acute lung injury (Tay et al., 2020) . One of the key challenges posed by COVID-19 pandemic is the paucity of proven effective therapies to date (ASHP, 2020) . Although attempting to inhibit the virus' replication may be a viable option in the early stages of the disease, this approach appears to be less effective in the later stages, in which the inflammatory phenotype dominates the clinical picture (Polak et al., 2020) , thus endorsing the hypothesis that properly timed anti-inflammatory therapeutic strategies could improve patients' clinical outcomes and prognosis (Mehta et al., 2020) . One plausible approach to impede this virally induced hyperinflammation in patients with severe COVID-19 pneumonia is through interleukin-1 (IL-1) antagonism (Van De Veerdonk and Netea, 2020) . Anakinra is a bio-engineered form of the naturally occurring IL-1 receptor antagonist (IL-1ra) that blocks the biologic activity of the proinflammatory cytokines IL-1α and IL-1β (Van De Veerdonk and Netea, 2020) and is approved for the treatment of a broad variety of diseases (Cavalli and Dinarello, 2018) . Anakinra safety profile (Kullenberg et al., 2016) combined with the utility of IL-1 antagonism in conditions that share many immunologic and clinical features similar to the hyperinflammatory phase of COVID-19 (Cardone et al., 2020) warranted assessing anakinra as a potential therapeutic agent in severe COVID-19 pneumonia with associated hyperinflammation. Currently, there is no known published prospective clinical trial evidence supporting efficacy of anakinra for the treatment of COVID-19 pneumonia. However, limited data on use of anakinra in patients with COVID-19 pneumonia exist (Huet et al., 2020; Cavalli et al., 2020'a') . We aimed to evaluate the efficacy of anakinra in patients who were admitted to hospital for severe COVID-19 pneumonia requiring oxygen therapy. We hypothesize that anakinra might be beneficial in this patient population. The OMA-COVID-19 study is a single-centre prospective interventional trial evaluating the effectiveness of anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy against retrospectively derived historical controls. Patients were included in the interventional arm if they were aged >18 years and admitted to Sultan Qaboos University Hospital (SQUH), a 490-bed referral teaching hospital in Muscat, Oman, with severe COVID-19-pneumonia defined as bilateral lung infiltrates on a chest x-ray, a positive SARS-CoV-2 RT-PCR assay, and any of the following; (1) respiratory rate >30 breaths/min and peripheral capillary oxygen saturation (SpO2) of < 90% on room air, or (2) SpO2 ≤93% under oxygen ≥ 6 L/min, or (3) acute respiratory distress syndrome (ARDS). Exclusion criteria included the refusal of the patient to participate, patients already on invasive mechanical ventilation, known allergy to anakinra, pregnant or breast-feeding women, active or untreated tuberculosis, apparent risk for gastrointestinal perforation (abdominal surgery, active inflammatory bowel disease, or active endoscopy-proven peptic ulcer disease), active cancer, active bacterial or fungal infection, chronic liver disease, absolute neutrophil count of < 1.5×10⁹/L, or platelet count of <50×10⁹/L, and patients who had been enrolled concurrently in other clinical trials. The historical control group was identified retrospectively from the SQUH COVID-19 register, which commenced on April 1, 2020, and encompassed all hospitalized patients with COVID-19 disease. Patients who did not receive anakinra and fulfilled the same inclusion and exclusion criteria as those of the interventional arm were included as historical controls. The OMA-COVID-19 study protocol was approved by the institutional medical research and ethics committee (REF. NO. SQU-EC/169/2020, MREC #2136) and registered at the international standard randomised controlled trial number (ISRCTN74727214). All patients were given both oral and written information by their physicians about anakinra and the study protocol and could either accept or refuse enrolment. Obtaining patients' written consent was mandatory for enrolment and their choice was documented in the institutional electronic medical record. The patients' agreement to the use of their data for research was also obtained. Patients in the interventional arm received subcutaneous anakinra (Swedish Orphan Biovitrum, Stockholm, Sweden) at a dose of 100 mg twice daily for 3 days, followed by 100 mg daily for a maximum of 7 days, in addition to the standard treatment at SQUH at the time and supportive care. The dose of anakinra was adjusted to renal function and reduced to one daily injection of 100 mg for the first 3 days, followed by an injection every other day for the next 7 days, in patients under dialysis or with a glomerular filtration rate of less than 30 mL/min. Historical controls received standard treatment and supportive care. Standard treatment at SQUH at the time included parenteral β-lactam antibiotics (intravenous ceftriaxone 2 g per day or intravenous piperacillin-tazobactam 4.5 g three times per day) for 7 days, a macrolide antibiotic (intravenous azithromycin 500 mg per day for 3 days), and thromboembolic prophylaxis for all hospitalized patients unless contraindicated. Supportive care comprised supplemental oxygen therapy and ventilatory support. Some patients in the interventional arm received a maximum of 3 doses of intravenous dexamethasone (6 mg per day) before enrolment. Many historical controls received 5 days course of intravenous methylprednisolone (40 mg twice per day for 5 days). The data were reported into an electronic database. Data were confidentially collected and coded according to the institutional regulation regarding patient information and confidential treatment of all data. The study design and data collection were approved by the institutional medical research ethics committee. Demographic and clinical characteristics, including age, sex, ethnicity, hypertension, diabetes, chronic cardiac, pulmonary, renal, hepatic, neurological diseases, and CXR severity index (Brixia score) were recorded. Clinical manifestations including fever, respiratory rate, oxygen saturation, oxygen therapy requirement were recorded at baseline and day 14, or discharge from hospital. Similarly, biomarkers of inflammation including, IL-6, CRP, serum ferritin, and D-dimer, and other laboratory parameters including, neutrophil, lymphocyte, platelet count, lactate dehydrogenase (LDH), alanine and aspartate aminotransferase, and creatinine were also recorded at baseline and day 14, or discharge from hospital. Plain chest x rays were done at admission and day 14 or discharge whichever is earlier. Chest radiologist independently reviewed and reported CXR Brixia scores for radiological grading of the severity of COVID-19 pneumonia. The main outcomes were the need for invasive mechanical ventilation (IMV) and inhospital death. Secondary outcomes included the differences in the mean oxygen therapy requirements between day 0 and day 4, day 14 or discharge, and change in the inflammatory biomarkers of disease severity (D-dimer, absolute lymphocyte count, serum ferritin, LDH, CRP, and IL-6 levels) between day 0 and day 14, or discharge from the hospital. In the interventional arm, day 0 corresponds to the date of initiation of anakinra. In the historical controls, day 0 corresponds to the first day during which each patient fulfilled the inclusion criteria defined for the interventional arm. Safety outcomes were occurrence -within 14 days -of invasive bloodstream infection (BSI), thrombocytopenia (platelet count <50×10⁹/L), neutropenia (absolute neutrophil count < 1.5×10⁹/L), increase in liver aminotransferase enzymes (defined as > five times the upper limit of normal), and injection site reactions. Descriptive statistics were used to describe the data. For categorical variables, frequencies and percentages were reported. Differences between groups (anakinra versus the historical cohort) were analysed using Pearson's  2 tests (or Fisher's exact tests for expected cells <5). For continuous variables, mean and standard deviation were used to present the data while analysis was performed using Student's t-tests. For nonnormal distributed continuous variables, median and interquartile range (IQR) were used to summarize the data and analysis performed using Wilcoxon-Mann-Whitney tests. Outcomes were adjusted for the significant differences at baseline using multivariate logistic regression utilizing the simultaneous method. An a priori twotailed level of significance was set at <0.05 level. Statistical analyses were conducted using STATA version 16.1 (STATA Corporation, College Station, TX, USA). Graselli and colleagues (Graselli et al., 2020) reported that more than 80% of patients with severe COVID-19 pneumonia required IMV. We hypothesized that, to reduce the need for IMV by 50% between the anakinra arm and the historical cohort (80% to 30%), 46 patients were needed (23 on each arm) with power of 90% at the 5% alpha (significance) level. Because of missing data and losses to follow-up, an additional 23 patients were added for a total of 69 subjects (study sample). From June 15 to July 25, 2020, 45 consecutive patients were enrolled in the interventional arm. From April 1 to June 14, 2020, 24 consecutive patients with the same inclusion and exclusion criteria as the interventional arm were retrospectively identified from the hospital COVID-19 register and were used as historical controls. Baseline demographic, clinical characteristics, CXR Brixia severity index, and laboratory biomarkers of inflammation of patients in the two groups are compared in Table 1 . Significant differences between the two groups were a lower Asian ethnicity (22% vs 50%; p = 0.029), a longer duration of symptoms before inclusion (10 vs 7 days; p = 0.009), a lower proportion of patients treated with hydroxychloroquine (0 vs 21%; p = 0.004), a lower proportion of patients treated with ≥4 doses of 40 mg of intravenous methylprednisolone (2% vs 54%; p = <0.001), a higher lymphocyte count (1.6 vs 0.8 ×10⁹ /L; p < 0.001), and a lower proportion of patients with D-dimer > 1 mg/L FEU (26% vs 50%; p = 0.044) in the anakinra-treated than in the historical control group, respectively. Clinical inclusion criteria, requirements for oxygen therapy, and disease severity as determined by Brixia severity score and biomarkers defined severity thresholds were balanced between the anakinra-treated and the historical patients (Table 1) . A total of 33/45 (73%) of the patients in the interventional arm and 17/24 (71%) of the historical patients met the laboratory definition for hyperinflammation (CRP > 150 mg/L, or IL-6 > 60 pg/mL, or ferritin > 1500 μg/L). The need for IMV occurred in 14 (31%) of 45 patients in the anakinra-treated group compared with 18 (75%) of 24 patients in the historical group (p < 0.001) ( Table 2 ). The treatment effect of anakinra on the need for IMV persisted and remained significant even after multivariate adjustment of the significant variables at baseline (adjusted odds ratio (aOR), 0.27; 95% confidence interval (CI): 0.07-0.97; p = 0.046) and when stratified by the presence (36% vs 76%; p = 0.016) or absence (17% vs 71%; p = 0.045) of hyperinflammation (Table 2 ). This treatment effect on the need for IMV was likewise demonstrated at day 4 (20% vs 58%; p = 0.033) and day 14 (23% vs 50%; p = 0.046) in the anakinra-treated compared to the historical group, respectively. In-hospital death occurred in 13 (29%) of 45 patients in the interventional group compared with 11 (46%) of 24 patients in the historical cohort (p = 0.082). This mortality difference did not reach statistical significance. Among the 40 patients in the interventional group who were either alive on day 14 or discharged, 25 (63%) were off oxygen supplementation (on ambient air) compared with only 6 (27%) in the historical group (p = 0.008) (Figure 1 ). The effect of anakinra on normalization/near normalization of the inflammatory biomarkers at day 14 or discharge was significant for IL-6 (6.6 vs 124 pg/mL; p < Brevibacterium species was isolated. Increases in alanine aminotransferase (>5 times upper limit) levels were observed in 14% and 9% of anakinra-treated and historical controls, respectively (p = 0.704). Neutropenia and thrombocytopenia occurred in 7% and 5% of anakinra-treated patients, respectively. No injection site reactions were observed. In this prospective, open-label, interventional trial (OMA-COVID-19) of hospitalized patients with severe COVID-19 pneumonia requiring high oxygen therapy, anakinra significantly reduced the need for invasive mechanical ventilation, improved respiratory function, and dampened COVID-19 associated hyperinflammation. Thus far, no specific treatment has been conclusively shown to reduce the need for IMV in patients with COVID-19 pneumonia requiring oxygen therapy. Similarly, no published clinical trial evidence on efficacy of anakinra in this patient population has been reported. Nonetheless, there are several encouraging reports from case series, retrospective and prospective cohorts on the use of anakinra in patients with COVID-19 pneumonia (Huet et al., 2020; Cavalli et al., 2020'a'; Navarro-Millán et al., 2020; Aouba et al., 2020; Pontali et al., 2020) . We demonstrated that anakinra as a therapeutic intervention for severely ill patients with COVID-19 pneumonia, has potential to avert the need for IMV. We found that 69% of anakinra-treated patients responded favourably and did not need IMV. This is in contrast with the historical patients where only 25% achieved this outcome (p < 0.001) suggesting that targeting IL-1 via the use of anakinra may be an effective approach to avoid IMV in these patients. Interestingly, this treatment effect of anakinra was likewise noted in patients with and without demonstrable hyperinflammation. This unexpected, though interesting observation may plausibly be explained by the shortcoming of the biomarkers' thresholds used in this and other studies to define hyperinflammation. We believe these biomarker thresholds signify advanced inflammation and may underrecognize a subset of patients (labelled as without hyperinflammation) with early inflammation who may still benefit from the anti-inflammatory effect of anakinra. The therapeutic effect of anakinra on deferring need for IMV was not seen in the subset of patients who required non-invasive ventilation (59% vs 82%; p = 0.258). This latter observation suggests that there may be a therapeutic window -before extravagant respiratory failure -where anakinra might be most beneficial (Langer-Gould et al., 2020) . It may also suggest that low-dose subcutaneous anakinra may not be adequate to control inflammation in patients with advanced respiratory failure, a finding consistent with a previous report (Cavalli et al., 2020'a') . While the search for effective therapeutics for severe COVID-19 pneumonia is underway, oxygen therapy is currently the main means of supporting these patients. All patients in this study were severely ill and required high oxygen therapy at enrolment (Table 1) . Successful weaning from supplemental oxygen to room air oxygen-at day 14-was attained in 63% of patients in the interventional group compared with 27% of patients in the historical control group. This treatment effect was significant (p = 0.008) and could translate to a shorter time to recovery and to hospital discharge favouring hospital pandemic surge capacity. Several studies have indicated that a subset of patients with severe COVID-19 pneumonia experience hyperinflammatory state best inferred by a concurrent rise in biomarkers of inflammation above defined thresholds . Applying these thresholds, we found that 73% of anakinra-treated patients and 71% of historical patients had biomarker definition of hyperinflammation at inclusion denoting advanced stage, poor prognosis, and possibly biological plausibility for anakinra. The antiinflammatory effect of anakinra was examined in our study. Patients who received anakinra showed significant reduction in IL-6, CRP, LDH, and D-dimer levels compared with historical controls (Table 2 and Figure 2) . Although, anakinra has been reported to reduce COVID-19 mortality in small observational studies (ASHP, 2020), our study showed no significant difference in inhospital mortality between anakinra treated (29%) and historical group (46%) (p=0.159). We believe that the inability of our study to demonstrate mortality benefit may be explained by late initiation of anakinra, large proportion of patients in the advanced hyperinflammatory state at inclusion (73%), and possibly an underpowered design rather than true lack of a treatment effect. Whether earlier administration of anakinra will decrease in-hospital mortality is unknown. Despite lack of demonstrable, statistically significant between-group mortality difference, the treatment effect of anakinra may still be clinically relevant. Intriguingly, a significant deference in mortality favouring anakinra was observed for Arab ethnicity (24% vs 67%; p = 0.013). This ethnicity difference in treatment outcomes, disadvantaging Asian ethnicity, is consistent with reported worse clinical outcomes from COVID-19 in this population (ICNARC, 2020; Pan et al., 2020) . Although cause of death was not systematically examined in our study, seven patients (54%) and nine patients (82%) died from ARDS in the anakinra and historical group, respectively. Additionally, two patients (one from each group) presumably died from systemic thromboembolism. A distinctive mark of the OMA-COVID-19 is the use of Brixia score, a CXR severity scoring system designed exclusively for assessment of COVID-19 pneumonia (Borghesi and Maroldi, 2020'a') . In a previous study, Brixia score of 8 or more was found to be predictive for risk of in-hospital death (Borghesi et al., 2020'b') . In our study, 39/41 (95%) of anakinra-treated patients and 19/22 (86%) of historical controls had CXR Brixia score of ≥ 8 at inclusion denoting that majority of patients in both groups have severe disease and are at high risk of death. When no contraindication, combination of β-lactam and macrolide antibiotics was prescribed at our institution as standard of care for hospitalized patients with severe COVID-19 pneumonia. A total of 98% and 100% of patients in the intervention and historic groups received β-lactam antibiotics while 84% and 92% received azithromycin, respectively. Nearly half the patients in both cohorts were prescribed oseltamivir (47% and 46%, respectively) at discretion of the treating physician. All patients in both groups were treated with prophylactic-dose low molecular weight heparin for thromboprophylaxis. More patients in the historical control group (54% vs 2%; p < 0.0.001) received longer therapeutic courses of steroids (methyl prednisone) which might have created bias obscuring detection of a significant mortality benefit from anakinra. It is important to mention that corticosteroids are the only therapeutic intervention thus far to conclusively prove a mortality benefit for patients with COVID-19 pneumonia (Lamontagne et al., 2020) . A total of 21% of historical controls received hydroxychloroquine in combination with azithromycin compared to none in the interventional group. This combination has been shown in a recent systematic review and meta-analysis to significantly increase mortality (Fiolet et al., 2020) and may have introduced bias favouring anakinra. Treatment with anakinra was safe and well tolerated and its discontinuation did not result in respiratory deterioration. We observed similar rates of bacteraemia (11% vs 18%) and increase in alanine aminotransferase (14% vs 9%) in anakinra-treated and historical controls, respectively. All bacteraemia events were self-limited, and none required antimicrobial therapy. The similar occurrence of transient changes in liver enzymes in both groups suggests that hyperinflammation may be the culprit (Cavalli and Dagna, 2020'b') . Neutropenia and thrombocytopenia occurred in 7% and 5% of anakinra treated patients respectively versus none observed amongst historical controls. We acknowledge several limitations of the study. First, small sample size with potential hindrance to definitive conclusions. Second, lack of a randomized design which could have introduced bias. Third, the intervention group was compared with historical control group during a 10-week period possibly introducing a non-contemporaneous bias. Fourth, the historical controls differed from the anakinra-treated patients in several potentially confounding variables. Despite the aforementioned limitations, OMA-COVID-19 has several strengths. Unlike previous reports, this study is one of a few clinical trials and the first to be published. OMA-COVID-19 enrolled a heterogenous population with severe COVID-19 pneumonia but with variable degrees of inflammation and different requirements for oxygen therapy permitting assessment of the treatment effect in various clinical phenotypes. Our study suggests that anakinra could represent an effective treatment option for patients with severe COVID-19 pneumonia and may confer benefit by averting need for invasive mechanical ventilation and hastening weaning off oxygen therapy in substantial number of patients. In patients with severe COVID-19 pneumonia and high oxygen requirement, anakinra is safe and effective therapeutic approach to defer mechanical ventilation, hasten weaning from supplemental oxygen, and control SARS-CoV-2 triggered inflammation. Our study provided further evidence of the utility of anakinra in this patient population. Further adequately powered randomized clinical trials are warranted to corroborate our findings. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. This study was sponsored by the medical research centre of Sultan Qaboos University, Oman. OQ (a non-pharmaceutical national company in Oman) funded the cost of anakinra. AST: aspartate aminotransferase. f. Change in lymphocyte count between D0 (day 0) and D14 (day 14) among patients in the anakinra group (comparison data available for 35 patients). *D0 refers to the day of initiation of anakinra and D14 refers to day 14 since initiation of anakinra. IL-6: interleukin-6. CRP: C-reactive protein. LDH: lactate dehydrogenase. 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series Assessment of Evidence for COVID-19-Related Treatments Accessed 12 An inflammatory profile correlates with decreased frequency of cytotoxic cells in coronavirus disease 2019 COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression Chest Xray severity index as a predictor of in-hospital mortality in coronavirus disease 2019: A study of 302 patients from Italy Lessons learned to date on COVID-19 hyperinflammatory syndrome: considerations for interventions to mitigate SARS-CoV-2 viral infection and detrimental hyperinflammation Anakinra therapy for non-cancer inflammatory diseases Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study Anakinra for COVID-19: how to interpret elevations in serum liver enzymes Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response Anakinra for severe forms of COVID-19: a cohort study ICNARC COVID-19 Study Case Mix Program Database Understanding COVID-19: what does viral RNA load really mean? The Lancet Infectious Diseases Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study Longterm safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes A living WHO guideline on drugs for covid-19 Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19 COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet Use of anakinra to prevent mechanical ventilation in severe COVID-19: A case series A dynamic immune response shapes COVID-19 progression The impact of ethnicity on clinical outcomes in COVID-19: A systematic review Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal The trinity of COVID-19: immunity, inflammation and intervention We would like to thank the medical research centre of Sultan Qaboos University, Oman, and the Oman Qaboos company for supporting this research.